Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Instagram Outage Disrupts Thousands of U.S. Users 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
OXFORD, United Kingdom, Aug. 25, 2017 -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will announce its financial results for the second quarter and half year ended 31 July 2017 on 31 August 2017.
Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the second quarter and half year results press release and a replay of the call will also be available through the Company's website, www.summitplc.com.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Therapeutics Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office) | Tel: +44 (0)1235 443 951 +1 617 225 4455 | |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7213 0880 | |
| N+1 Singer (Broker) Aubrey Powell / Lauren Kettle | Tel: +44 (0)20 7496 3000 | |
| MacDougall Biomedical Communications (US media contact) Karen Sharma | Tel: +1 781 235 3060 [email protected] | |
| Consilium Strategic Communications (Financial public relations, UK) Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey Neville | Tel: +44 (0)20 3709 5700 [email protected] | |
-END-
